<DOC>
	<DOCNO>NCT01594242</DOCNO>
	<brief_summary>The purpose study well understand effect chemotherapy medication bortezomib cancer cell . The investigator therefore take blood bone marrow sample patient myeloma receive bortezomib see investigator detect autophagy myeloma cell bone marrow immune cell blood . Subjects eligible doctor planning treat bortezomib first time myeloma .</brief_summary>
	<brief_title>Autophagy Induction After Bortezomib Myeloma</brief_title>
	<detailed_description>PRIMARY OBJECTIVE : The primary objective study determine whether administration bortezomib lead increase cellular autophagy , determine electron micrographs peripheral blood lymphocyte primary myeloma cell patient receive single-agent bortezomib . SECONDARY OBJECTIVES 1 . To determine optimal time autophagy assessment patient receive bortezomib . 2 . To explore whether high level autophagy associate resistance bortezomib therapy . 3 . To validate primary assay confirm baseline stability number autophagic vesicle per cell 4 . To compare result autophagy measurement peripheral blood mononuclear cell bone marrow plasma cell</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Bortezomib</mesh_term>
	<criteria>Histologically confirm multiple myeloma ( newly diagnose relapsed patient permit ) No one line prior therapy contain bortezomib . No prior therapy proteasome inhibitor . For subject receive previous bortezomib , least partial response bortezomibcontaining therapy , without progression bortezomibcontaining therapy within 90 day stop bortezomib . Planned therapy , determine patient 's treating physician , bortezomibcontaining regimen Medically suitable undergo study procedure , include oneweek washout prior therapy , one week observation , one week singleagent bortezomib Provision write informed consent Exclusion Criteria Age &lt; 18 year ( though demographic myeloma make highly unlikely child meet inclusion criterion ) Treatment antimyeloma agent , include corticosteroid , thalidomide , lenalidomide , within 7 day prior study baseline bone marrow biopsy . Inability understand inform consent document unwillingness consent . Written informed consent must obtain patient study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>multiple myeloma</keyword>
	<keyword>bortezomib</keyword>
	<keyword>proteasome inhibitor</keyword>
</DOC>